Literature DB >> 1648110

CT of fibrolamellar hepatocellular carcinoma.

P Soyer1, A Roche, M Levesque, P Legmann.   

Abstract

We retrospectively evaluated 10 patients with pathologically proven fibrolamellar hepatocellular carcinoma (FLHCC) to assess the utility of CT (n = 9), ultrasound (n = 10), angiography (n = 9), and MR (n = 3). The tumors were solitary in 6 of 10 patients, well delineated in 7 of 10, and hypervascular in 8 of 10. With use of multimodality imaging techniques, a central scar was demonstrated in 3 of 10 patients, calcifications in 4 of 10, dilated intrahepatic ducts in 2 of 10, thrombosis of a segmental portal branch in 2 of 10, and lymph node involvement in 3 of 10. Computed tomography was the most accurate technique for diagnosis and staging. Magnetic resonance imaging helped establish the correct diagnosis in one patient. This report emphasizes the wide variability of imaging features of FLHCC and the predominant role of CT for suggesting the diagnosis.

Entities:  

Mesh:

Year:  1991        PMID: 1648110     DOI: 10.1097/00004728-199107000-00001

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  4 in total

Review 1.  [Radiological diagnosis of primary hepatic malignancy].

Authors:  Benjamin Henninger; Johannes Petersen; Werner Jaschke
Journal:  Wien Med Wochenschr       Date:  2013-02-08

2.  Constitutive activation of nuclear factor-kappa B (NF-kB) signaling pathway in fibrolamellar hepatocellular carcinoma.

Authors:  Wei Li; Dongfeng Tan; Maryam J Zenali; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2009-01-01

3.  Aggressive surgical management of fibrolamellar hepatocellular carcinoma.

Authors:  A W Hemming; B Langer; P Sheiner; P D Greig; B R Taylor
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

4.  Focal nodular hyperplasia of the liver: radiologic findings.

Authors:  K Shamsi; A De Schepper; H Degryse; F Deckers
Journal:  Abdom Imaging       Date:  1993
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.